Clinical Trials & Noteworthy Treatments For Brain Tumors
Tumor Necrosis Therapy (TNT)
http://virtualtrials.com/tcln.cfm
Copyright 2004 The Musella Foundation For Brain Tumor Research & Information, Inc.
The materials provided at this site are for informational purposes and are not intended for use as diagnosis
or treatment of a health problem or as a substitute for consulting a licensed medical professional.
A new experimental drug called Cotara is being investigated for the
treatment of newly diagnosed and recurrent high grade brain tumors. This
drug is an antibody which is combined with radioactive iodine. Cotara binds
to proteins within the nucleus of necrotic (dead and dying) cells which are
present in most malignant tumors. These cells may account for 50% of
tumors and are primarily found at the center of the tumor. Cotara is given
directly into the brain tumor as a continuous infusion through catheters.
Once Cotara is delivered, it remains within the tumor and the attached
radioactive iodine bombards the neighboring living tumor cells with
radiation. Each successive treatment with Cotara kills more tumor cells and
increases the necrotic regions, allowing it to be more effective with each
treatment. Cotara has been used in patients who have previously received
chemotherapy and/or radiation therapy.
 |
|
|
|
|
|
Showing Treatment 1 to 6 of 6 |
|
Location |
|
Last Updated |
|
|
|
Details |
|
Open-Label Dose Confirmation and Dosimetry Study of Interstitial 131I-chTNT-1/B mAb (Cotara®) for the Treatment of Recurrent Glioblastoma Multiforme |
|
Philadelphia, PA USA |
|
08/26/2007 |
|
|
|
|
|
Details |
|
Open-Label Dose Confirmation and Dosimetry Study of Interstitial 131I-chTNT-1/B mAb (Cotara®) for the Treatment of Recurrent Glioblastoma Multiforme |
|
Charleston, SC USA |
|
08/26/2007 |
|
|
|
Details |
|
Open-Label Dose Confirmation and Dosimetry Study of Interstitial 131I-chTNT-1/B mAb (Cotara®) for the Treatment of Recurrent Glioblastoma Multiforme |
|
Philadelphia, PA USA |
|
08/26/2007 |
|
|
|
|
|
Details |
|
Open-label, Dose Confirmation and Dosimetry Study of Interstitial 131-I chTNT-1/B mAb (Cotara®) for the Treatment of Recurrent Glioblastoma Multiforme (GBM) |
|
Tustin, CA USA |
|
07/31/2007 |
|
|
|
Details |
|
Iodine I 131 Monoclonal Antibody TNT-1/B (131I MOAB TNT-1/B), in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme |
|
Detroit, MI USA |
|
02/03/2006 |
|
|
|
|
|
Details |
|
An Open-label, Dose Confirmation and Dosimetry Study of Interstitial 131I-chTNT-1/B MAB (COTARA) for the Treatment of Glioblastoma Multiforme (GBM) at 1st of 2nd Relapse |
|
Baltimore, MD USA |
|
11/06/2005 |
|
|
|